7358 related articles for article (PubMed ID: 17718062)
1. [Cancer screening with PET: advantages and limitations].
Kawada S; Suzuki Y; Hinohara S; Koide S; Ono Y; Ashikaga H
Rinsho Byori; 2007 Jul; 55(7):656-67. PubMed ID: 17718062
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of whole-body cancer screening using 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography: a preliminary report.
Terauchi T; Murano T; Daisaki H; Kanou D; Shoda H; Kakinuma R; Hamashima C; Moriyama N; Kakizoe T
Ann Nucl Med; 2008 Jun; 22(5):379-85. PubMed ID: 18600415
[TBL] [Abstract][Full Text] [Related]
3. 2-[Fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography versus whole-body diffusion-weighted MRI for detection of malignant lesions: initial experience.
Komori T; Narabayashi I; Matsumura K; Matsuki M; Akagi H; Ogura Y; Aga F; Adachi I
Ann Nucl Med; 2007 Jun; 21(4):209-15. PubMed ID: 17581719
[TBL] [Abstract][Full Text] [Related]
4. Analysis of various malignant neoplasms detected by FDG-PET cancer screening program: based on a Japanese Nationwide Survey.
Minamimoto R; Senda M; Terauchi T; Jinnouchi S; Inoue T; Iinuma T; Inoue T; Ito K; Iwata H; Uno K; Oku S; Oguchi K; Tsukamoto E; Nakashima R; Nishizawa S; Fukuda H; Murano T; Yoshida T
Ann Nucl Med; 2011 Jan; 25(1):45-54. PubMed ID: 20953985
[TBL] [Abstract][Full Text] [Related]
5. Application of positron emission tomography imaging to cancer screening.
Yasuda S; Ide M; Fujii H; Nakahara T; Mochizuki Y; Takahashi W; Shohtsu A
Br J Cancer; 2000 Dec; 83(12):1607-11. PubMed ID: 11104553
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of head and neck cancer with 18F-FDG PET: a comparison with conventional methods.
Kresnik E; Mikosch P; Gallowitsch HJ; Kogler D; Wiesser S; Heinisch M; Unterweger O; Raunik W; Kumnig G; Gomez I; Grünbacher G; Lind P
Eur J Nucl Med; 2001 Jul; 28(7):816-21. PubMed ID: 11504077
[TBL] [Abstract][Full Text] [Related]
7. Cancer screening with FDG-PET.
Ide M
Q J Nucl Med Mol Imaging; 2006 Mar; 50(1):23-7. PubMed ID: 16557201
[TBL] [Abstract][Full Text] [Related]
8. PET/CT for the staging and follow-up of patients with malignancies.
Poeppel TD; Krause BJ; Heusner TA; Boy C; Bockisch A; Antoch G
Eur J Radiol; 2009 Jun; 70(3):382-92. PubMed ID: 19406595
[TBL] [Abstract][Full Text] [Related]
9. Performance profile of FDG-PET and PET/CT for cancer screening on the basis of a Japanese Nationwide Survey.
Minamimoto R; Senda M; Uno K; Jinnouchi S; Iinuma T; Ito K; Okuyama C; Oguchi K; Kawamoto M; Suzuki Y; Tsukamoto E; Terauchi T; Nakashima R; Nishio M; Nishizawa S; Fukuda H; Yoshida T; Inoue T
Ann Nucl Med; 2007 Nov; 21(9):481-98. PubMed ID: 18030580
[TBL] [Abstract][Full Text] [Related]
10. The value of 18F-fluorodeoxyglucose positron emission tomography with the additional help of tumor markers in cancer screening.
Shen YY; Su CT; Chen GJ; Chen YK; Liao AC; Tsai FS
Neoplasma; 2003; 50(3):217-21. PubMed ID: 12937856
[TBL] [Abstract][Full Text] [Related]
11. Ionising radiation-free whole-body MRI versus (18)F-fluorodeoxyglucose PET/CT scans for children and young adults with cancer: a prospective, non-randomised, single-centre study.
Klenk C; Gawande R; Uslu L; Khurana A; Qiu D; Quon A; Donig J; Rosenberg J; Luna-Fineman S; Moseley M; Daldrup-Link HE
Lancet Oncol; 2014 Mar; 15(3):275-85. PubMed ID: 24559803
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive Oncologic Imaging in Infants and Preschool Children With Substantially Reduced Radiation Exposure Using Combined Simultaneous ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance Imaging: A Direct Comparison to ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography.
Gatidis S; Schmidt H; Gücke B; Bezrukov I; Seitz G; Ebinger M; Reimold M; Pfannenberg CA; Nikolaou K; Schwenzer NF; Schäfer JF
Invest Radiol; 2016 Jan; 51(1):7-14. PubMed ID: 26309185
[TBL] [Abstract][Full Text] [Related]
13. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
[TBL] [Abstract][Full Text] [Related]
14. "One-stop-shop" staging: should we prefer FDG-PET/CT or MRI for the detection of bone metastases?
Heusner T; Gölitz P; Hamami M; Eberhardt W; Esser S; Forsting M; Bockisch A; Antoch G
Eur J Radiol; 2011 Jun; 78(3):430-5. PubMed ID: 19945240
[TBL] [Abstract][Full Text] [Related]
15. Utility of 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography and positron emission tomography/computed tomography imaging in the preoperative staging of head and neck squamous cell carcinoma.
Roh JL; Yeo NK; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
Oral Oncol; 2007 Oct; 43(9):887-93. PubMed ID: 17207656
[TBL] [Abstract][Full Text] [Related]
16. Improved detection of second primary cancer using integrated [18F] fluorodeoxyglucose positron emission tomography and computed tomography for initial tumor staging.
Choi JY; Lee KS; Kwon OJ; Shim YM; Baek CH; Park K; Lee KH; Kim BT
J Clin Oncol; 2005 Oct; 23(30):7654-9. PubMed ID: 16234527
[TBL] [Abstract][Full Text] [Related]
17. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.
Sperti C; Bissoli S; Pasquali C; Frison L; Liessi G; Chierichetti F; Pedrazzoli S
Ann Surg; 2007 Dec; 246(6):932-7; discussion 937-9. PubMed ID: 18043094
[TBL] [Abstract][Full Text] [Related]
18. Post-treatment surveillance of head and neck cancer: pitfalls in the interpretation of FDG PET-CT/MRI.
Meerwein CM; Queiroz M; Kollias S; Hüllner M; Veit-Haibach P; Huber GF
Swiss Med Wkly; 2015; 145():w14116. PubMed ID: 25701645
[TBL] [Abstract][Full Text] [Related]
19. [The role of whole body 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in the management of unknown primary tumors].
Wu ZJ; Zhang YX; Wei H; Jia Q
Zhonghua Yi Xue Za Zhi; 2007 Aug; 87(32):2253-6. PubMed ID: 18001544
[TBL] [Abstract][Full Text] [Related]
20. Does whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography have an advantage over thoracic positron emission tomography for staging patients with lung cancer?
Aquino SL; Fischman AJ
Chest; 2004 Sep; 126(3):755-60. PubMed ID: 15364753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]